glp-1 medication interactions Exploring the Side Effects of Receptor Agonist: To Ensure Its Optimal Positioning PDB-101: Molecule of the Month:

November 14th, 2025: Three New Jersey Cases Added to Expanding GLP-1 Drug MDL A federal judicial panel has transferred three additional lawsuits from New Jersey into the growing multidistrict litigation involving claims that Eli Lilly and Novo Nordisk minimized the safety risks associated with GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Trulicity

So here are my thoughts on GLP-1 receptor agonists from a gastroenterologists perspective

No need to return the product

Our main finding is that LFD is associated with an increase in circulating GLP-1 levels in IBS patients

After stopping, her first cycle off medication was 38 days (longer than usual), her second cycle was 32 days (getting closer), and by her third cycle and beyond she was back to her normal 28-29 days

Individual variation exists: Some people maintain more of their weight loss than others, particularly those who've established sustainable lifestyle changes during treatment